MDGL (Madrigal Pharmaceuticals) Future Price to Earnings

Corporate emblem and logo of Madrigal Pharma (MDGL)

The forward P/E chart for Madrigal Pharmaceuticals (MDGL) reflects market expectations, where a metric value of 60.70 is driven by its first-mover status in NASH therapy and potential for high margins. High barriers to entry and patent protection create a robust moat against competitors. The business is currently focusing on the large-scale deployment of the distribution network for its primary drug within the US region.

MDGL - Madrigal Pharmaceuticals Inc Projected Price to Earnings Ratio over the range 07/04/2022 - 11/16/2026

Analytical breakdowns for Madrigal Pharmaceuticals

- current price and projected stock value:
General company analysis:MDGL madrigalpharma.com
Brand item of Madrigal Corp

The resilience of Madrigal Pharmaceuticals (MDGL) is based on the monopoly status of the first drug for the therapy of nonalcoholic steatohepatitis. The company's expected P/E multiple visualizes market expectations for the commercialization of this asset. This indicator is calculated by dividing the current quote by the projected net income. This metric measures investors' willingness to pay a premium for future revenue growth. A decrease in the ratio signals that the business is undervalued relative to its fundamental prospects.

Competitors of Madrigal Pharmaceuticals (MDGL)

Projected Price to Earnings ASND (Ascendis Pharma Inc.)|CORT (Corcept Therapeutics Corp) - Future Price to Earnings Multiple|Future Price to Earnings rhythmtx.com RYTM|AKRO - Projected Price to Earnings|Metsera Therapeutics - Forward P/E Multiple|Projected Price to Earnings Ratio MoonLake Pharma|CRNX (Crinetics) - Projected Price to Earnings|NAMS: Market Cap to Future Earnings Ratio|SLNO (Soleno Therapeutics Corp) - Forward P/E Multiple|Forward P/E Multiple Amicus Therapeutics|Forward P/E Multiple ETNB|Future Price to Earnings AGIO (Agios)|Future Price to Earnings structuretx.com GPCR|MiMedx Corp (MDXG) - Projected Price to Earnings Ratio|RZLT - Future Price to Earnings|LXRX: Future Price to Earnings|MBX Biosciences, Inc. (MBX) - Future Price to Earnings|ALT - Market Cap to Projected Earnings|Future Price to Earnings Aardvark Pharma|Sagimet Biosciences Inc (SGMT) - Market Cap to Projected Earnings|Future Price to Earnings bioagelabs.com (BIOA)|Projected Price to Earnings Biomea Fusion, Inc. BMEA|Future Price to Earnings Quince QNCX|GUTS (Fractyl Health Inc.) - Price to Expected Earnings Ratio|VTVT: Projected Price to Earnings|Forward Price to Earnings Multiple agapeatpgroup.com (ATPC)|PLUR (Pluri) - Projected Price to Earnings|Price to Future Earnings Ratio SYBX|Future Price to Earnings Lipocine Corporation|matinasbiopharma.com (MTNB) - Market Cap to Projected Earnings|Forward P/E Multiple SPRB|Projected Price to Earnings Galecto, Inc. GLTO|Future Price to Earnings Carmell Corporation CTCX|Future Price to Earnings Multiple LUMO|ONVO: Projected Price to Earnings|Future Price to Earnings Multiple RDUS (Radius Recycling Inc.)